Ocular Therapeutix’ bold vision to redefine retinal disease treatment

What It Covers

Ocular Therapeutix CEO Praveen Duggal outlines how the company's lead drug candidate EXPaxley, a tunable dissolvable hydrogel delivering a tyrosine kinase inhibitor, targets two core failures in wet AMD treatment: 40% patient dropout rates and long-term vision loss from fibrosis, with SOL1 trial readout expected Q1 2026.

Key Questions Answered

• •Patient dropout economics: 40% of wet AMD patients in the U.S. abandon monthly or bimonthly injection regimens within the first year, resulting in blindness. Reducing dropout by even 10% would prevent approximately 250,000 additional cases of blindness annually in the U.S. alone, generating substantial cost savings for payers who bear escalating care costs for blind patients.
• •Fibrosis as the overlooked failure mode: Even patients who remain compliant with anti-VEGF injections lose vision after two to five years due to fibrosis and atrophy, not rebleeding. The cyclical swelling from monthly injections damages retinal nerve cells similarly to repeated concussions. Continuous VEGF suppression via sustained-release formats reduces this scarring and improves long-term visual outcomes.
• •ELutix platform tunability: The ELutix hydrogel platform releases drug over a programmable duration — one month for DEXTENZA, approximately ten months for EXPaxley — by adjusting PEG bond composition around the implant. The API itself is not pegylated. The hydrogel fully dissolves post-release, leaving no residual implant material, which eliminates a key safety concern for intraocular sustained-delivery devices.
• •Non-proliferative diabetic retinopathy opportunity: In the Healios study, a single EXPaxley injection reduced vision-threatening complication rates from 37.5% in controls to zero at 48 weeks in non-proliferative diabetic retinopathy patients. This population — largely asymptomatic working-age adults — has under 1% treatment penetration today, representing a commercially untapped market that any successful VEGF-targeting drug historically expands into.
• •Regulatory risk mitigation via SPA: Ocular followed FDA's February 2023 draft guidelines for retinal disease trials precisely, earning a Special Protocol Assessment agreement for SOL1. Investors evaluating clinical-stage biopharma should treat SPA agreements as a concrete de-risking signal, particularly in volatile macro environments where regulatory unpredictability elevates the value of pre-agreed trial design alignment with the agency.